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Abstract In Her2-positive breast cancer patients, inhi-
bition of epidermal growth factor receptor 2 (ErbB2)-
signaling is often combined with chemotherapy and
radiotherapy. The risk of cardiac toxicity after anthracy-
clines and radiotherapy is recognized, but little is known
about increased risk when these treatments are combined
with ErbB2 inhibition. This study investigated whether
ErbB2 inhibition increased radiation or anthracycline-
induced toxicity. In an in vitro study, human cardiomyo-
cytes were treated with irradiation or doxorubicin, alone
or in combination with trastuzumab, and evaluated for cell
survival and growth. Groups of mice received 0 or 14 Gy
to the heart, alone or in combination with lapatinib, or
3 9 4 mg/kg doxorubicin alone or in combination with
lapatinib. Mice were evaluated 40 weeks after treatment
for cardiac damage. Changes in cardiac function (99mTc-
Myoview gated SPECT) were related to histomorphology
and microvascular damage. Radiation or doxorubicin-
induced cardiomyocyte toxicity (in vitro) were not exac-
erbated by trastuzumab. Cardiac irradiation of mice
decreased microvascular density (MVD) and increased
endothelial damage in surviving capillaries (decrease
alkaline phosphatase expression and increased von
Willebrand factor), but these changes were not exacer-
bated by lapatinib. Inflammatory responses in the irradi-
ated epicardium (CD45? and F4/80? cells) were
significantly reduced in combination with lapatinib. Irra-
diation, doxorubicin, and lapatinib each induced cardiac
fibrosis but this was not further enhanced when treatments
were combined. At the ultra-structural level, both lapatinib
and doxorubicin induced mitochondrial damage, which
was enhanced in combined treatments. Lapatinib alone
also induced mild changes in cardiac function but this was
not enhanced in the combined treatments. Trastuzumab
did not enhance direct radiation or anthracycline toxicity
of cardiomyocytes in vitro. Lapatinib did not enhance the
risk of radiation or anthracycline-induced cardiac toxicity
in mice up to 40 weeks after treatment, but mitochondrial
damage was more severe after doxorubicin combined with
lapatinib.
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Introduction
Cardiovascular damage has been reported as a long-term
toxicity in breast cancer survivors previously treated with
radiotherapy (RT) and anthracycline chemotherapy (CT)
[1]. Prospective functional imaging studies show that
*40 % of left-sided breast cancer patients treated with RT
develop asymptomatic cardiac perfusion defects within
2 years and about 16 % eventually develop wall-motion
abnormalities [2–4]. Yearly, 1.5 million new breast cancer
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patients are diagnosed worldwide who will undergo RT,
CT, surgery, and/or adjuvant hormonal therapy. Approxi-
mately 15–20 % of breast cancers show a highly aggressive
subtype, characterized by epidermal growth factor receptor
2 (ErbB2) overexpression. Such cancers are fast-growing,
highly invasive, resistant to CT and RT and are therefore
associated with higher risk for recurrence [5, 6]. Epidermal
growth factor receptor 1 (ErbB1) is also expressed in
several human tumors, including breast cancer, and makes
significant contributions to invasion and growth of tumors
[7].
The established role of ErbB1 and ErbB2 in breast
cancer makes them attractive therapeutic targets. Trast-
uzumab, a humanized anti-ErbB2 monoclonal antibody, is
the most prominent, first-line agent for ErbB2 (HER2)-
overexpressing metastatic breast cancer [8]. Clinical stud-
ies using trastuzumab confirmed the benefits of inhibiting
ErbB2 signaling, including inhibition of p27Kip1, activation
of PTEN tumor suppressor gene and induction of G1 cell
cycle arrest [9]. Adjuvant treatment with trastuzumab for
operable breast cancer improves overall survival rate in
Her2-positive breast cancer patients by *30 % and redu-
ces the risk of recurrence by *50 % [10, 11]. However,
heart failure occurs in 1.7–4.1 % of patients treated with
trastuzumab and cardiac toxicity lead to discontinuation of
the adjuvant treatment in 19 % of the patients [10–12].
ErbB2 is an orphan receptor that has no ligand binding
site but dimerizes with other ligand-bound EGRF receptors
(HER3, HER4). One of the most common ligands of the
EGFR pathway in the heart is neuregulin-1. Targeting both
ErbB1 and ErbB2 is hypothesized to have superior thera-
peutic effects relative to single-agent treatment. Dual
inhibitor lapatinib (GW572016) is a small molecule,
reversible inhibitor of the tyrosine kinase activities of
ErbB1 and ErbB2 at equal potency. Lapatinib works by
blocking the signaling transduction to Ras/Raf MAPKs and
the PI3K/Akt pathway, which leads to increased apoptosis
and decreased cellular proliferation. Perez and colleagues
reviewed 44 studies in which lapatinib (as monotherapy or
in combination with previously given anthracyclines or
trastuzumab) induced low levels of cardiac toxicity, as
detected by reversible decreased left ventricle ejection
fraction (LVEF) [13].
The mechanisms whereby cardiac toxicity occurs after
ErbB2 inhibition is not fully understood, since non-
malignant cells do not over-express ErbB2. However,
ErbB2 signaling and the ligand Neuregulin-1 are known to
play a crucial role in survival and growth of cardiac
myocytes [14, 15]. Moreover, a recent study demonstrated
that irradiation inhibited ErbB2 signaling in rat hearts until
the onset of fibrosis after 10 weeks. As fibrosis progressed,
ErbB2 and the EGFR ligand neuregulin were significantly
upregulated, presumably as an attempt to regenerate the
myocardium [16]. This raises the question whether delayed
inhibition of ErbB2 after CT or RT could lead to increased
cardiac toxicity.
Little is known about the long-term cardiac outcome of
lapatinib in combination with anthracycline CT or irradi-
ation. In this study, we first investigated whether blocking
of ErbB2 enhanced the toxicity of radiation- or doxorubicin
(Dox)-treated cardiomyocytes in vitro. We subsequently
investigated the influence of combined ErbB1/2 inhibition
in mice treated with cardiac irradiation or systemic Dox.
For these studies lapatinib was given for 20 weeks in the
chow, either at the time of irradiation or Dox (direct), or
delayed until 20 weeks after irradiation or Dox. This was
designed to mimic clinical treatment protocols and to
investigate the influence of lapatinib on the short- and long-
term damage repair process following irradiation or anth-
racyclines. Structural and functional changes were moni-
tored at 40 weeks after treatment to determine whether
ErbB1/2 inhibition caused increased cardiac damage or
inhibited recovery after radiation or anthracycline
treatment.
As far as we are aware, this is the first study that
characterizes in detail long-term cardiac toxicity after la-
patinib in combination with irradiation or Dox.
Methods
Cell culture conditions and treatment
Human cardiac myocytes (HCM) from Promocell (Hei-
delberg, Germany) were cultured in DMEM (Gibco,
Invitrogen) supplemented with 10 % fetal calf serum, 1 %
penicillin, and 1 % streptomycin at 37 C with 5 % CO2.
The HCM express markers of early stage differentiation
such as GATA-4 and sarcomeric alpha-actin and act more
like progenitor cells with capacity for proliferation. For
irradiation experiments, cells were seeded in 96-well plates
(1,000 per well) and irradiated with 0, 2.5, 5, or 10 Gy
(137Cs irradiation, with a dose rate of 0.66 Gy/min) before
exposure to 0, 0.1, 1, or 10 lg/ml trastuzumab (Roche,
from the Netherlands Cancer Institute pharmacy) for 14 or
21 days. Cells were then washed (39 with PBS) to remove
drugs and evaluated for cell viability. For Dox experi-
ments, 4,000 cells per well were seeded and treated with 0,
0.0025, 0.025, 0.25, 2.5, 25, and 250 lg/ml Dox (Doxo-
rubicin hydrochloride 2 mg/ml PCH, from the Netherlands
Cancer Institute pharmacy) and trastuzumab (0–10 lg/ml)
for 3 days, washed and evaluated for cell viability directly
or re-incubated with trastuzumab until evaluation at
14 days. Cell viability was detected by cell counting kit-8
(CCK-8, Sigma, Zwijndrecht, the Netherlands) following
the manufacturer’s protocol.
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Mice and treatments groups
Male C57BL/6 mice, aged 8–12 weeks (Charles River
Laboratories, France) were randomly allocated to receive
0 Gy or 14 Gy to the heart, or 4 mg/kg Dox intraperitoneal
(i.p.) weekly for 3 weeks. Separate cohorts of animals were
included for irradiation or anthracycline combined with
lapatinib, as well as age matched controls. Lapatinib (from
the Netherlands Cancer Institute pharmacy) was mixed
with standard mouse chow to a final concentration of
0.48 g/kg. Assuming consumption of 5 g chow/mouse/day,
this is equivalent to 100 mg/kg/day. A pilot study with
100 mg/kg/day given in chow or by oral gavages resulted
in the same plasma concentration (mean 946 ng/ml and
909 ng/ml lapatinib after chow diet and oral gavages).
Lapatinib diet was either started 7 days before irradiation
or Dox (direct schedule) to achieve steady state plasma
levels, or delayed until 20 weeks after treatment (Fig. 1).
Irradiation was with 250 kV X-rays, operating at 12 mA
and filtered with 0.6-mm Copper. The dose rate was
0.94 Gy/min, with a field size of 10.6 9 15 mm (including
the whole heart and up to 30 % lung volume); the rest of
the mouse was shielded with lead. For irradiation,
unanesthetized mice were immobilized in a prone position
in acrylic perspex jigs. Each treatment group comprised
10–15 mice (n = 125 in total). Experiments were in
agreement with the Dutch law on animal experiments and
welfare, and in line with the international Guide for the
Care and Use of Laboratory Animals (Eighth edition).
Tissue preparation for histology
At termination of the experiment, the heart was perfused via
the aortic arch (retro-grade), under lethal sodium pentobarbital
anesthesia (18 mg per mouse, i.p.), with PBS (frozen sections)
or PBS followed by 1 % paraformaldehyde (paraffin sec-
tions). The heart was then quickly excised before freezing on
dry ice or immersion in 1 % paraformaldehyde.
Cross-sections were cut at the level of the mid-hori-
zontal plane from fixed paraffin-embedded tissues (4 lm)
or frozen tissues (7 lm).
Frozen sections
An anti-CD31 antibody (1:50, Becton&Dickinson) was
used to visualize cardiac vasculature. To determine func-
tional changes in the microvasculature, a histochemical
staining with Naphtol AS-MX/DMF and fast Blue BB salt
was performed to detect endothelial cell alkaline phos-
phatase. Sections were also reacted with antibodies against
von Willebrand Factor (vWF) (1:4000, Abcam, Cam-
bridge, USA) as a marker of thrombotic changes. All
sections were processed identically, with precisely the
same incubation times for the primary and secondary
antibody and diaminobenzidine (DAB) solution (Sigma,
Zwijndrecht, the Netherlands).
For quantification of microvascular changes, five random
fields (409 objective) of the heart were photographed with a
CCD 2 Color Microscope system, including a Zeiss Axio-
Cam color camera (Axiocam HRc, Zeiss, Go¨ttingen, Ger-
many). A computerized morphometry system (Leica Qwin
V3, Leica, Rijswijk, the Netherlands) was used to quantify
the MVD of CD31 positive structures. Vessels \1.5 or
[200 lm2 were automatically excluded from the measure-
ments. Photographs of whole sections stained for ALP and
vWF were taken with an Aperio scanner (Scanscope-XT,
Aperio technologies, Vista, USA) using 409 objective.
Analyses of the percentage myocardium, excluding endo-
cardium, positive for each marker were done with a com-
puterized morphometry system (Leica Qwin V3).
Direct
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Fig. 1 Schedule overview.
Schematic representation of
schedules for lapatinib given for
20 weeks in the chow, starting
at the time of irradiation or
doxorubicin (direct), or starting
20 weeks after irradiation or
doxorubicin (delayed)
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Paraffin sections
To determine the extent of inflammation, sections were
immuno-labeled with anti-CD45 antibody (1:400, Becton
& Dickinson, Franklin lakes, USA). To detect alterations in
the number of macrophages sections were stained with
anti-F4/80 (1:300, AbD Serotec, Dusseldorf, Germany) and
counted per left ventricle (LV) myocardial area.
All sections were processed identically; therefore, dif-
ferences between the treatments are due to DAB identifi-
cation of the relevant protein. Interstitial collagen was
determined in the myocardium based on Sirius red staining.
Photographs of the LV wall, excluding the septum, were
taken using a 409 objective (Leica DFC320). Interstitial
collagen was quantified in five randomly selected areas of
the subendocardium and myocardium of the LV (409
objective) and results were expressed as percentage tissue
positive for Sirius red relative to myocardial area. The
number of CD45? cells per section was counted separately
in the epicard and myocard to determine the extent of
inflammation. Morphometric parameters were analyzed
using a computerized morphometry system (Leica Qwin
V3). Transverse sections were stained with hematoxylin
and eosin (H&E) to check for alterations in the myocar-
dium and blood vessels. A semi-quantitative scoring sys-
tem was used, whereby for the blood vessels 1 indicates
one mild/severe morphological event (degeneration of the
coronary arterioles, dilation of capillaries in myocardium
accompanied by edema in stroma or clotting-like materials
in coronary vessels), 2 indicates two morphological events,
and 3 indicates [2 severe morphological events. For the
myocardium, a score of 1 indicated atrophy, 2 indicated
degeneration or hypertrophy, and 3 indicated more than
two events.
Electron microscopy (EM)
Tissues were fixed in Karnovsky’s fixative, followed by
1 % osmiumtetroxide in 0.1 M cacodylate-buffer. After
washing, pellets were stained with Ultrastain 1 (Leica,
Vienna, Austria), followed by ethanol dehydration. Finally
the cells were embedded in a mixture of DDSA/NMA/
Embed-812 (EMS, Hatfield, U.S.A), sectioned and stained
with Ultrastain 2 (Leica, Vienna, Austria) and analyzed
with a CM10 electron microscope (FEI, Eindhoven, the
Netherlands).
Gated SPECT/CT
Gated single photon emission computed tomography
(gSPECT) acquisitions were made with a small-animal
NanoSPECT/CT (Bioscan Europe, Ltd., Paris, France).
Animals were anesthetized with Hypnorm (Fentanyl
0.26 mg/kg/Fluanisone 8.33 mg/kg, VetaPharma, Ltd.,
Leeds, UK) and Dormicum (Midazolam, 4.17 mg/kg,
Roche, Woerden, the Netherlands) via i.p. injection (1:2:1
Hypnorm:H2O:Dormicum; 120 ll/mouse). Myoview (GE-
healthcare, Hoevelaken, the Netherlands) was labeled with
1–1.5 ml 99mTc-pertechnetate. For detailed information see
Seemann et al. [17]. Quantitative analysis of the recon-
structed datasets was performed on a clinical e.soft (syngo-
based) workstation (Siemens Medical Solutions, Siemens
AG, Erlangen, Germany), using algorithms to automati-
cally reconstruct a count based 3D model of the dimensions
of the left ventricular (LV) end-diastolic and systolic vol-
umes (EDV, ESV). Subsequently, a LV time volume curve
and its first derivative were generated. The ejection fraction
(EF) was calculated based on the difference between EDV
and ESV divided by EDV and peak filling rate (PFR)
(EDV/s) was calculated from the Fourier-fitted curves.
Statistics
Data are expressed as mean ± SEM and groups were
compared using non-parametric Mann–Whitney exact
U-tests. Group differences were considered statistically
significant at p \ 0.05. Statistical analyses were performed
using SPSS version 20.
Results
HER2 inhibition did not decrease myocyte cell viability
in vitro
Exposure of human cardiomyocytes for 3 days to Dox
induced a dose-dependent decrease in cell viability. How-
ever, combination of Dox with trastuzumab did not further
decrease myocyte cell viability (Fig. 2a). When Dox was
removed after 3 days and cells were evaluated at 14 days
after treatment, cell proliferation was not affected by the
presence of trastuzumab. Prior exposure to [0.025 lg/ml
Dox inhibited cardiomyocyte growth, but this was inde-
pendent of trastuzumab exposure (Fig. 2b).
Cardiomyocyte cell viability decreased after radiation
doses of 2.5–10 Gy, when assessed at 14 or 21 days after
treatment, but there was no further decrease in cell viability
in combination with trastuzumab (Fig. 2c, d).
Mouse survival and weight
Irradiation with 14 Gy alone caused no premature deaths
and few deaths occurred in combination with direct (7 %) or
delayed lapatinib (12 %). Heart and body weights were
slightly lower after irradiation (Fig. 3a and Table S1). There
were more unscheduled deaths after treatment with Dox
388 Breast Cancer Res Treat (2013) 141:385–395
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Fig. 2 Cardiomyocyte viability
after ErbB2 inhibition. Fig a/b:
Human cardiomyocytes were
treated with doxorubicin
(0–250 lg/ml) and trastuzumab
(0–10 lg/ml) for 3 days. Cells
were then washed (39 with
PBS) to remove drugs and
evaluated for cell viability
directly (2a) or re-incubated
with trastuzumab only until
evaluation at 14 days (2b).
Each symbol represents the
mean (±SEM) of three
experiments and results are
expressed as percentage cell
survival. Fig c/d: Human
cardiomyocytes were irradiated
(0, 2.5, 5, or 10 Gy) and then
exposed to trastuzumab
(0–10 lg/ml) for 14 days (c) or
21 days (d) before evaluation of
cell viability. Each symbol
represents the mean (±SEM) of
three experiments and results
are expressed as percentage cell
survival
Fig. 3 Kaplan-Meier estimated
of overall survival shown for
mice treated with lapatinib
alone or in combination with
radiation or doxorubicin.
Survival data are shown for
mice treated with radiation
(a) or doxorubicin (b) alone or






mice and age matched control
groups (p \ 0.05; Mann–
Whitney U-test)
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(27 %), especially when combined with lapatinib (36 and
33 % deaths for direct and delayed lapatinib) (Fig. 3b; Table
S2). Since the group analyses were done on material from
surviving animals only, this probably represents an under-
estimate of the total toxic effects of Dox. Both heart and
body weights were also lower after Dox alone or in com-
bination with lapatinib compared to age-matched control.
Radiation-induced microvascular damage
MVD decreased significantly after 14 Gy radiation alone
but the decline was not further enhanced by combination
with either direct or delayed lapatinib treatment (Fig. 4a).
There were no changes in MVD after Dox treatment alone
or in combination with lapatinib (data not shown). Radia-
tion-induced changes in MVD were accompanied by
endothelial damage, as shown by a marked decrease in
ALP activity (Fig. 4b) and an increased expression of the
thrombotic endothelial marker vWF after irradiation alone
(Fig. 4c). None of these endothelial changes were more
severe after combined treatments with lapatinib then after
irradiation alone (Fig. 4b, c). Endothelial damage (ALP) or
thrombotic changes in the microvascular (vWF) were not
detected in Dox-treated mice (data not shown).
Radiation-induced inflammation
Irradiation alone led to a significant increase in CD45?
cells and F4/80? cells in the epicardium (Fig. 5) but not in
the myocardium (data not shown). Strikingly, direct or
delayed lapatinib decreased CD45? and F4/80? cells in
the irradiated epicardium, compared to irradiation alone
(Fig. 5a, b). There were no significant inflammatory
responses seen in Dox-treated mice (data not shown).
Irradiation- and doxorubicin-induced cardiac fibrosis
Cardiac fibrosis was significantly increased by irradiation or
lapatinib alone, when administrated directly (Fig. 6a). Lapat-
inib (either direct or delayed) did not further enhance the
fibrosis induced by irradiation. There was also a significant
increase in cardiac fibrosis after Dox alone, but this was not
further enhanced by either direct or delayed lapatinib (Fig. 6b).
Structural and morphological alterations
H&E stained sections were semi-quantitatively analyzed for
changes in the myocardium and blood vessels. There were





Fig. 4 Microvascular alterations after ErbB2 inhibition alone or in
combination with irradiation. a MVD per unit area expressed as
number of microvessels per mm2. b ALP positive tissue areas as % of
total tissue. c vWF positive tissue areas as % of total tissue *p \ 0.05
compared to age-matched untreated controls. Each value represents
the mean (±SEM) for minimal five mice per group. Ctrl control; Lap
lapatinib; IR irradiation; IR?lap irradiation combined with lapatinib
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or in combination with direct lapatinib. However, when
delayed lapatinib was given to irradiated mice there was a
trend for increased myocardial and blood vessel damage,
including dilation of capillaries, degeneration of coronary
arteries, degeneration of the myocardium, and hypertrophy
of the myocardium (Fig. 7). No severe changes were
detected in Dox-treated mice that survived until 40 weeks.
Examination of prematurely sacrificed, sick animals did
demonstrate damage but this group comprised only a few
mice, sacrificed at various times after treatment, so no semi-
quantitative analysis was done. Electron microscopy (EM)
analysis indicated small changes in myocyte morphology,
like local vacuolization, after Dox or lapatinib treatment
alone. Changes were enhanced when Dox was combined
with lapatinib, either direct or delayed. Focal damage was
seen with degenerative changes in the mitochondria, cloudy-
swollen phenotype and disorganized, disrupted Z-bands in
some cardiomyocytes, but normal looking mitochondria and
Z-bands in adjacent cells (Fig. 8).
Lapatinib decreased left ventricle function
Cardiac function tests, determined by gated SPECT/CT,
showed increases in ESV after lapatinib alone (34 and
16 % increase for direct and delayed schedules) (Fig. 9).
Similar increases in EDV were seen (11 and 9 % for direct
and delayed schedules) (data not shown). This resulted in
decreased EF (22 and 9 % decreases after direct and
delayed lapatinib) (Fig. 9). PFR, maximum down slope of
left-ventricular volume, also showed significant decrease
after lapatinib treatment (20 and 21 % after direct and
delayed lapatinib) (Fig. 9). Neither 14 Gy nor 3 9 4 mg/kg
Dox induced significant changes in cardiac function, either
given alone or in combination with lapatinib.
Discussion
In this study, we investigated the effect of direct and
delayed inhibition of EGFR signaling combined with
irradiation or Dox on cardiomyocyte survival, morpho-
logical damage, and heart function. We demonstrated that
inhibiting ErbB2 in combination with irradiation or anth-
racyclines did not further decrease myocyte cell viability
in vitro. Combined inhibition of ErbB1 and ErbB2 also did
not enhance radiation or Dox induced cardiac damage in
mice. Indeed, the radiation-induced inflammatory respon-
ses were inhibited by lapatinib.
Direct Delayed A
B
Fig. 5 Inflammatory changes after ErbB2 inhibition alone or in
combination with irradiation. a Quantification of CD45?cells b and
of F4/80?cells per section in the epicardium. Each value represents the
mean (±SEM) for minimal five mice per group. *p \ 0.05 compared to
age-matched untreated controls. n.d. not determined. Ctrl control; Lap
lapatinib; IR irradiation; IR?lap irradiation combined with lapatinib
Direct Delayed A
B
Fig. 6 Fibrotic changes after ErbB2 inhibition alone or in combina-
tion with irradiation or doxorubicin. a Collagen per unit area
expressed as percentage of total tissue for animals treated with
irradiation. b Collagen per unit area expressed as percentage of total
tissue for animals treated with doxorubicin *p \ 0.05 compared to
age-matched untreated controls. Each value represents the mean
(±SEM) for minimal five mice per group. n.d. not determined. Ctrl
control; Lap lapatinib; DOX doxorubicin; DOX?Lap doxorubicin
combined with lapatinib; IR irradiation; IR?lap irradiation combined
with lapatinib
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Inhibition of ErbB2 in HER2-overexpressing breast
cancers became a standard (adjuvant) treatment as it results
in improvement of outcome [18]. Often this is combined
with anthracycline CT [19]. In addition, most patients
receive adjuvant RT, either after breast conserving surgery
or mastectomy [20]. Previous studies have shown an
increase in cardiac events after combining RT with anth-
racyclines, such as decline in LVEF or congestive heart
failure [11, 13, 21]. Long term follow up studies with
ErbB2 inhibiting agents combined with these modalities
are ongoing to determine both efficacy and safety, espe-
cially with regard to cardiac toxicity (ALTTO study; BIG
2-06/N063D).
EGFR signaling, including ligand NRG-1, plays an
important role in adult cardiomyocyte survival, since it
activates the pro-survival PI3K/pathway and stimulates
cardiomyocyte maintenance and function [22]. Previous
studies in our lab, demonstrated the ability of the mouse
heart to compensate functionally for significant structural
damage after previous irradiation [17]. Compensatory
mechanisms and pro-survial pathways might play a role in
maintaining cardiomyocyte function in a damaged heart, at
least until the extent of damage overwhelms the potential
for stimulated survival. Sridharan et al. [16] recently
demonstrated upregulation of ErbB signaling in the irra-
diated rat heart in parallel with developing cardiac fibrosis,
leading to the suggestion that ErbB signaling and pro-
survival pathways are activated in an attempt to regenerate
the myocardium. Moreover, inactivation of ErbB4 in ven-
tricular muscle cells led to a severe dilated cardiomyopa-
thy, demonstrating the important role of ErbB signaling in
the myocardium [23].
This raises the question of whether inhibition of these
pathways could impair attempts of the damaged heart to




Fig. 7 Histological changes in the myocardium and blood vessels at
40 weeks after treatment with irradiation or doxorubicin alone or in
combination with lapatinib. H&E sections of the heart of mice that
survived treatment with irradiation alone or in combination with
lapatinib. Blood vessel and myocardium were scored for cardiac
events at 40 weeks after treatment. Each symbol represents the score
of one mouse (minimal five mice per group). a Age-matched control
heart. b Dilated capillaries (open arrow) and edema in the stroma
(dark arrow) of an irradiated heart. c Hyaline-like degeneration of the
coronary arterioles (open arrows). d Atrophy of the myocardium
(small, misshapen myocytes, and separated from each other, open
arrows). (e) Degeneration of the myocardium. f Focal fibrosis (open
arrows) and degeneration of endocardium
392 Breast Cancer Res Treat (2013) 141:385–395
123
regenerate. Similar to the findings of Sridharan et al. [16],
we found increased expression of both ErbB2 and ErbB4 in
mouse hearts at 40 weeks after irradiation, in parallel with
developing fibrosis (Supplementary Fig. 1). However, this
upregulation was not inhibited in the presence of lapatinib.
Our data also do not indicate cardiac dysfunction after
radiation alone or in combination with lapatinib, in contrast
to the mild but significant changes in cardiac function after
lapatinib alone (Fig. 9). These data are consistent with the
important role of ErbB signaling to maintain myocardium
functionality and imply that that this compensatory
mechanisms initiated by irradiation still operate in the
presence of lapatinib.
Treatment of adult human cardiomyocytes, which have
low expression of HER2, with trastuzumab, did not alter
cell viability, nor did it enhance toxicity induced by either
radiation or Dox (Fig. 2). This is consistent with the
knowledge that anthracyclines cause acute irreversible
damage to the cardiomyocytes through generation of free
radicals and cardiomyocyte apoptosis [24], whereas trast-
uzumab-induced cardiac toxicity is dose-dependent and
largely reversible [25]. The doses of trastuzumab we used
were sufficient to cause significant reduction in viability in
HER2-overexpressing tumor cells (data not shown), but the
cardiomyocytes were less sensitive to ErbB2 inhibition.
Some studies, using HER2-overexpressing breast cancer
cells, have shown that inhibition of PI3K -pathway may be
bypassed by lateral activation of other members of the
HER family (Her3) [26, 27]. This raises the possibility, that
activation of this compensatory feedback loop could
thereby stimulate survival of cardiomyocytes.
Our in vitro results contrast somewhat with a recently
published study by Hasinoff et al., in which pretreatment of
isolated neonatal rat cardiac myocytes with HER1/HER2
inhibitor lapatinib potentiated doxorubicin-induced myocyte
damage, assessed by LDH release and disrupted sarcomeres,
although there was no enhancement of doxorubicin-induced
apoptosis. A major difference between our study and that of
Hasinoff is that they used neonatal cardiomyocytes and
neuregulin is essential for the developing heart, which
probably increases cardiomyocyte sensitivity to ErbB2
inhibition. In our study, we investigated the effects of
trastuzumab (ErbB2 inhibitor) on adult cardiomyocyte sur-
vival after Dox or irradiation. We did not look at changes in
cardiomyocyte function or morphology in vitro. However,
our EM study from in vivo experiments would suggest
enhanced cardiomyocyte damage from the combination of
lapatinib and Dox, consistent with the data of Hasinoff.
Our findings suggest that trastuzumab or lapatinib
induced cardiac toxicity acts by different mechanisms than
anthracyclines or radiation. This raises the possibility that
the cardiac toxicity seen in clinical studies where ErbB2
inhibition is combined with anthracyclines could be due to
indirect effects, for example endothelial cell dysfunction
and loss, with secondary damage to the cardiomyocytes.
We have previously shown [17] that local cardiac irra-
diation induces microvascular loss and damage. The
current study shows that irradiation-induced endothelial





A B C D E 
Fig. 8 Mitochondrial changes in the myocardium after ErbB2
inhibition. Electron microscopic images of the myocardium of mice
treated with lapatinib alone or in combination with doxorubicin at
40 weeks after treatment. a Age-matched control (n = 3); cardio-
myocytes show organized sarcomeres characterized by parallel
myofilaments anchored to Z bands and mitochondria were perfectly
aligned and packed. b Doxorubicin treatment alone (n = 3); myofil-
ament arranged regularly and mitochondria were aligned with focal
vacuolization (arrow). c Lapatinib treatment alone (n = 3); focal
damage per cardiomyocyte. Mitochondrial volume increased, mito-
chondrial cristae were fuzzy and had a cloudy swollen pheno-
type (arrow). d Direct lapatinib set up combined with doxorubicin
(n = 3); e delayed lapatinib set up combined with doxorubicin
(n = 3); disorganized mitochondria, mitochondrial cristae were fuzzy
and had a cloudy swollen phenotype (arrow), increased volume of
mitochondria. MI mitochondria; MF myofibril; Z z-bands; Dic Discus
interculatis
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dysfunction and loss was not further enhanced by lapatinib,
either when given at the time of irradiation (direct) or
delayed for 20 weeks. Mechanisms of radiation-induced
cardiac toxicity include activation of TGFb and production
of chemokines and pro-inflammatory cytokines, which are
largely independent of the PI3K-pathway determining
cardiomyocyte survival. However, the MAPK pathway has
been implicated in regulation of permeability in endothelial
cells [28], something we found to be increased by irradi-
ation. These observations are consistent with the concept
that mechanisms of radiation-induced cardiac damage do
not involve ErbB signaling.
Slow turnover tissues, like the myocardium, have a low
proliferative capacity and a small stem-cell component, and
therefore have a limited ability to repair damage. Radiation-
induced cardiac toxicity is initiated by an acute inflamma-
tory response, which progresses to fibrosis without proper
tissue regeneration [29]. We found that the inflammatory
response initially activated by irradiation was decreased by
lapatinib. We can speculate that, since the MAPK pathway
mediates myocardial pro-inflammatory cytokine production,
inhibiting MAPK pathway with lapatinib may decrease the
pro-inflammatory cytokine production [30, 31]. However,
we have no data to support this hypothesis.
A further consequence of irradiation is the development
of fibrosis. Similar to previous studies, our study showed
increased cardiac fibrosis after irradiation or Dox alone.
However, this was not further enhanced by lapatinib. On
the other hand, 20 weeks of lapatinib alone in the direct set
up induced fibrosis in mice sacrificed at 40 weeks. This is
in contrast to no increase in fibrosis when lapatinib was
delayed until 20 weeks and continued until sacrifice at
40 weeks. This might be explained by the delayed fibrotic
response of the myocardium, which required time to
develop after cessation of the lapatinib. We did not eval-
uate mice at later follow-up times than 40 weeks.
Changes in the microvasculature after Dox alone or with
lapatinib were not seen. Nevertheless, fibrosis and degen-
erated cardiomyocytes (EM study) and 27–36 % animal
lethality, as well as decreased cell viability in vitro, do
indicate doxorubicin-induced damage to the myocardium
via cardiomyocytes. Although anthracyclines induce acute
damage, clinical symptoms are mostly detectable months
or years after treatment [32]. Therefore, besides acute
myocardial damage, late and indirect microvascular dam-
age may occur at later times.
We conclude that ErbB2 inhibition did not enhance
direct radiation or anthracyclines toxicity of cardiomyo-
cytes in vitro. Radiation-induced microvascular damage
was not further enhanced by ErbB2 inhibition and the
inflammatory response was decreased. Myocardial damage
was induced by anthracyclines but not further enhanced by
ErbB2 inhibition. Treatment of mice with the ErbB 1/2-
blocking agent lapatinib did not further enhance the risk of
radiation or anthracycline-induced cardiac toxicity up to
40 weeks after treatment.
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Fig. 9 Cardiac function (EF, ESV, and PFR) measured by gated
SPECT at 40 weeks after treatment with irradiation or doxorubicin
alone or in combination with lapatinib or sham treatment. Values
represent mean ± SEM (8–14 mice in each treatment group),
*p \ 0.05 compared to age-matched untreated controls. Ctrl control;
Lap lapatinib; DOX doxorubicin; DOX?Lap doxorubicin combined
with lapatinib; IR irradiation; IR ? lap irradiation combined with
lapatinib
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